Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients

[1] Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403

[2] Steliarova-Foucher E(2006)Aromatase inhibitors in breast cancer: an overview Oncologist 11 553-562

[3] Lortet-Tieulent J(2011)Tamoxifen in early-stage estrogen receptor- positive breast cancer : overview of clinical use and molecular biomarkers for patient selection Onco Targets Ther 4 1-11

[4] Rosso S(2007)The what, why and how of aromatase inhibitors : hormonal agents for treatment and prevention of breast cancer Int J Clin Pract 61 2051-2063

[5] Coebergh JWW(2007)Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet (London, England) 369 559-570

[6] Comber H(2002)Review for in clinicians managing aromatase inhibitors in breast cancer survivors : not just for oncologists Mayo Clin Proc 85 560-566

[7] Altundag K(2014)Selective estrogen receptor modulators: tissue specificity and clinical utility Clin Interv Aging 9 1437-1452

[8] Ibrahim NK(1993)Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women Bone Min 22 87-94

[9] Criscitiello C(2012)Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer Breast Cancer Targets Ther 4 91-101

[10] Fumagalli D(2013)WNT signaling in bone homeostasis and disease: from human mutations to treatments Nat Med 19 179-192

[1] Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403

[2] Steliarova-Foucher E(2006)Aromatase inhibitors in breast cancer: an overview Oncologist 11 553-562

[3] Lortet-Tieulent J(2011)Tamoxifen in early-stage estrogen receptor- positive breast cancer : overview of clinical use and molecular biomarkers for patient selection Onco Targets Ther 4 1-11

[4] Rosso S(2007)The what, why and how of aromatase inhibitors : hormonal agents for treatment and prevention of breast cancer Int J Clin Pract 61 2051-2063

[5] Coebergh JWW(2007)Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet (London, England) 369 559-570

[6] Comber H(2002)Review for in clinicians managing aromatase inhibitors in breast cancer survivors : not just for oncologists Mayo Clin Proc 85 560-566

[7] Altundag K(2014)Selective estrogen receptor modulators: tissue specificity and clinical utility Clin Interv Aging 9 1437-1452

[8] Ibrahim NK(1993)Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women Bone Min 22 87-94

[9] Criscitiello C(2012)Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer Breast Cancer Targets Ther 4 91-101

[10] Fumagalli D(2013)WNT signaling in bone homeostasis and disease: from human mutations to treatments Nat Med 19 179-192